Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $8.37.

A number of brokerages have weighed in on ZNTL. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Wedbush reiterated a "neutral" rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th.

Zentalis Pharmaceuticals Price Performance

ZNTL traded down $0.04 during trading on Friday, reaching $1.33. The company had a trading volume of 623,162 shares, compared to its average volume of 1,447,322. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $5.44. The business's fifty day moving average price is $1.31 and its 200 day moving average price is $1.76. The company has a market cap of $95.69 million, a P/E ratio of -0.42 and a beta of 1.59.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.67). As a group, sell-side analysts predict that Zentalis Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insider Activity

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers acquired 21,000 shares of the stock in a transaction dated Wednesday, April 30th. The shares were bought at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the completion of the acquisition, the director directly owned 281,192 shares of the company's stock, valued at approximately $393,668.80. This trade represents a 8.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ZNTL. Charles Schwab Investment Management Inc. increased its holdings in Zentalis Pharmaceuticals by 22.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company's stock worth $1,507,000 after buying an additional 91,152 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Zentalis Pharmaceuticals during the fourth quarter worth $68,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Zentalis Pharmaceuticals by 50.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 345,039 shares of the company's stock worth $1,045,000 after buying an additional 115,901 shares during the last quarter. Primecap Management Co. CA increased its holdings in Zentalis Pharmaceuticals by 1.5% during the fourth quarter. Primecap Management Co. CA now owns 1,520,630 shares of the company's stock worth $4,608,000 after buying an additional 22,600 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its holdings in Zentalis Pharmaceuticals by 155.9% during the fourth quarter. Thrivent Financial for Lutherans now owns 70,641 shares of the company's stock worth $214,000 after buying an additional 43,036 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.